

The Cardiorenal Axis

From risk stratification to
personalized treatment

17.-18. January 2019

Getting to the heart of the matter
– targeted protein biomarker
discovery in cardiology

January 16, 2019



Sehr geehrte Frau Kollegin,
sehr geehrter Herr Kollege,

die klinische Medizin steht vor einschneidenden Umwälzungen. Nicht nur in die Behandlung von Tumorleiden, sondern auch von chronischen Erkrankungen und Stoffwechselstörungen halten kostspielige biologische Medikamente mehr und mehr Einzug. Die Zielstrukturen und Indikationen werden spezifischer, tradierte nosologische Entitäten werden aufgelöst zugunsten molekular und genetisch determinierter Krankheitsdefinitionen. Künstliche Intelligenz soll künftig Ärzte in der Diagnostik und Therapie unterstützen.

Die wirtschaftlichen Restriktionen, denen auch hoch entwickelte Gesundheitssysteme unterliegen, machen die Präzisierung von Behandlungsstrategien notwendig. Damit gilt wie seither, dass genetische und biochemische Diagnostik die unabdingbare Grundlage für rationale Therapieentscheidungen darstellt. Kaum eine moderne, teure Therapie lässt sich mehr ohne das molekulare Verständnis der zugrundeliegenden Erkrankungsmechanismen wirtschaftlich rechtfertigen.

Mit dem Symposium „Die kardiorenale Achse: Von der Risikostratifizierung zur personalisierten Behandlung“ wollen wir die Relevanz dieser Entwicklungen für Erkrankungen der Herzens und der Niere interdisziplinär und umfassend analysieren und Perspektiven für eine verbesserte Patientenversorgung in der Zukunft aufzeigen. Das Themenspektrum reicht daher von der Genetik über neue, prognostisch relevante Biomarker, Omics-Technologien und den Einsatz künstlicher Intelligenz in der Medizin.

Wie bereits im Jahr 2018 bieten wir in Zusammenarbeit und mit Unterstützung der Firma Olink Proteomics, Uppsala, Schweden, am Mittwoch, den 16. Januar 2019, ein Satellitensymposium zum Thema Einsatz des Proximity Extension Assay (PEA) in der Biomarker-Forschung an. Die Teilnehmerzahl dieser Veranstaltung ist begrenzt. Wir bitten daher um frühzeitige Anmeldung.

Wir hoffen, mit diesem Programm Ihr Interesse zu wecken und würden uns über viele Teilnehmer und gute Diskussionen freuen.

Prof. Dr. med. Bernhard K. Krämer
Univ. Prof. Dr. med. Winfried März
Prof. Dr. med. Christoph Wanner

Die Veranstaltung wurde bei der Landesärztekammer Baden-Württemberg zur Zertifizierung angemeldet.

Dear Colleagues,

Clinical medicine is facing major upheavals. Not only in the treatment of tumor diseases, but also of chronic diseases and metabolic disorders expensive biological drugs are more and more incorporated. Drug target structures and indications become more specific, traditional nosological entities are resolved in favor of molecular and genetically determined disease entities. Artificial intelligence is expected to assist doctors in diagnosis and therapy in the future.

The economic constraints, which are also subject to developed health systems, turn it unavoidable that treatment strategies become more precise. As it has been the case since then, genetic and biochemical diagnostics are the indispensable basis for rational therapeutic decisions. Hardly any modern, expensive therapy can be economically justified without the molecular understanding of the underlying disease mechanisms.

With the current Symposium „The Cardioresenal Axis: From Risk Stratification to Personalized Treatment“, we wish to analyze the relevance of these developments for heart and kidney diseases comprehensively and in an interdisciplinary fashion and identify perspectives for improved patient care in the future. The range of topics therefore extends from genetics to new, prognostically relevant biomarkers, omics technologies and the use of artificial intelligence in medicine.

As in 2018, on Wednesday, January 16, 2019, in cooperation with and with the support of Olink Proteomics, Uppsala, Sweden, we will be offering a satellite symposium on the use of the Proximity Extension Assay (PEA) in biomarker research. The number of participants of this event is limited. We therefore ask for early registration.

We hope to stimulate your interest with this program and would be pleased to welcome you in Mannheim.

*Prof. Dr. med. Bernhard K. Krämer
Univ. Prof. Dr. med. Winfried März
Prof. Dr. med. Christoph Wanner*

This event was submitted to the Medical Association for CME certification.

Program

Wednesday, January 16, 2019

Getting to the heart of the matter - targeted protein biomarker discovery for the advancement of precision medicine in cardiology and nephrology

11:15 **Arrival, registration, coffee**

11:45 **Lunch**

12:30 **Opening and overview on the topics of the meeting**

A. Ballagi, Uppsala, W. Koenig, Munich

Epidemiological studies to advance precision medicine

Chair: W. Koenig, Munich, W. März, Mannheim

12:40 Towards precision medicine for heart failure patients

F. Zannad, Nancy

13:25 Temporal patterns of blood biomarkers in patients with chronic heart failure

I. Kardys, Rotterdam

13:50 Role of proteomics in cardiovascular risk evaluation

M. Bom, Amsterdam

14:15 Systems medicine approaches in cardiovascular disease - from omics to biomarkers

T. Zeller, Hamburg

14:40 **Coffee**

Biomarker discovery in cardiovascular disorders

Chair: W. Koenig, Munich, W. März, Mannheim

15:15 Screening for new biomarkers in patients with cardiovascular disease

L. Wallentin, Uppsala

16:00 Biomarkers are guiding my therapies

A. Mebazaa, Paris

16:25 Comprehensive molecular profiling towards diagnostic biomarkers of acute aortic dissection

A. von Eckardstein, Zürich

16:50 Inflammatory signatures and risk of peripheral and cardiovascular autonomic neuropathies

C. Herder, Düsseldorf

17:15 **Plenary discussion**

Chair: W. Koenig, Munich, W. März, Mannheim

18:05 Closing remarks

A. Ballagi, Uppsala, W. März, Mannheim

18:15 End of the first meeting day

19:00 Evening event: Get together – Dorint Hotel

For further information on the proximity extension technique visit www.olink.com

Program

Thursday, January 17, 2019

09:00 **Registration, coffee**

09:15 **Welcome and introduction into the topic of the meeting**

B. K. Krämer, Mannheim, C. Wanner, Würzburg,
W. März, Mannheim and Graz

09:30 **Welcome address from the Mayor of the city of Ludwigshafen**

Jutta Steinruck, Ludwigshafen

Perspectives

Chair: Peter Lansberg, Groningen

09:45 The future of laboratory services
M. Floreani, Munich

10:15 The impact of health economics on clinical decision making
T. Wierzbicki, London

10:45 Novel approaches to risk stratification: From the acute setting to the general population
A. Beshiri, San Francisco Bay

11:15 **Coffee Break**

Genetics

Chair: H. Dieplinger, Innsbruck, and R. Patel, London

11:30 The genetics of lipoprotein (a): Anything new about it?
H. Schunkert, Munich

12:00 SuPAR as a biomarker of the cardio-renal axis: Lessons from the Emory Cardiovascular Biobank
S. Hayek, Ann Arbor

12:30 Genome wide association study of sclerostin
J. Tobias, Bristol

13:00 **Lunch Break**

13:30 **Poster**

Chair: Brigitte Zyriax, Hamburg, B. Fellström, Uppsala, N. Marx, Aachen

Workshop I: Omics technologies

Chair: S. Lorkowski, Jena, and A. Elbahry, Port Said

15:00 Ceramides – the rising stars in risk prediction
R. Laaksonen, Tampere

15:25 The potential of omics technologies in unraveling the biology of HDL
A. von Eckardstein, Zürich

15:50 Fatty acid profiling: with momentum after all
C. von Schacky, Munich

16:15 Genome wide associations and metabolomics: Focus on homoarginine
M. Kleber, Mannheim

16:40 **Coffee Break**

Workshop II: Bioinformatics, artificial intelligence

Chair: M. Herrmann, Graz, and W. Herrmann, Homburg

15:00 Personalized statin treatment in type 2 diabetes mellitus and hemodialysis
B. Genser, Wien

15:25 Tackling epistasis
B. Müller-Myhsok, Munich

15:50 Unraveling novel genes for familial hypercholesterolemia
A. Rimbert, Groningen

16:15 Machine learning in medicine – opportunities and hurdles
T. Sauter, Luxembourg

16:40 **Coffee Break**

Program

Thursday, January 17, 2019

Workshop III: Biomarkers in kidney disease

Chair: M. Zeier, Heidelberg

- 17:00 Cathepsin S: Predictive for vascular events?
 H. J. Anders, Munich
- 17:25 Circulating uromodulin inhibits vascular
 calcification by interfering with
 pro-inflammatory cytokine signalling
 J. Scherberich, Munich
- 18:50 The lung, the heart, and the kidney:
 What is the link?
 R. Bals, Homburg
- 18:15 Emerging biomarkers of the cardiorenal axis
 in the PANCAKE study
 M. Karakas, Hamburg
- 18:40 **End of the second day**
- 20:00 **Get together**

Workshop IV: Metabolism and Inflammation

Chair: A. Ritsch, Innsbruck

- 17:00 Inflammasome activation in vascular disease
 T. Speer, Homburg
- 17:25 Should we fortify food with vitamin D?
 S. Pilz, Graz
- 18:50 Dental health in chronic kidney disease –
 Results from the GCKD study
 C. Sommerer, Heidelberg
- 18:15 How to exploit the results of CANTOS in
 practice?
 A. Zirlík, Graz
- 18:40 **End of the second day**
- 20:00 **Get together**

Friday, January 18, 2019

Clinical topics I

Chair: W. Koenig, München

- 8:30 The future of CVD risk prediction
 L. Wallentin, Uppsala
- 9:00 Mechanisms of vascular disease in CKD
 J. Jankowski, Aachen
- 9:30 Triglycerides: marker or maker?
 M. Merkel, Hamburg
- 10:00 **Coffee Break**

Clinical topics II

Chair: D. Fliser, Homburg

- 10:15 From lipoproteins to lipidomics
 J. Chapman, Paris
- 10:45 PCSK9 update
 U. Laufs, Leipzig
- 11:15 SuPAR: a druggable target in kidney disease
 J. Reiser, Chicago
- 11:45 SGLT2 inhibition in heart and kidney disease
 C. Wanner, Würzburg
- 12:15 **Poster awards**
 B. Fellström
- 12:30 **Wrap up**
 B. K. Krämer, Mannheim, C. Wanner, Würzburg,
 W. März, Mannheim and Graz
- 12:45 **Lunch and farewell**

Poster Presentations

High sensitive cardiac Troponin I in hemodialysis patients

Artunc F. et al., Tübingen

Bariatric surgery associated weight loss positively affects clot lysis time

Baldia P.H. et al., Aachen

A new case of Tangier disease

Bobbert T. et al., Berlin

A critical update on solarium use and risk for malignant melanoma: meta-analysis and evidence-based systematic review

Burgard B. et al., Homburg

A sound microbiota in a sound body through apolipoprotein A-I and HDL: from mouse models to humans (OCTOPUS)

Chiesa Giulia et al., Milan

Effect of the MoKaRi diet on the Coropredict score

Dawczynski Christine et al., Jena

Effect of the MoKaRi diet on the plasma lipidome

Dawczynski Christine et al., Jena

Bile acids in patients with uncontrolled type 2 diabetes mellitus – The effect of two days of oatmeal treatment

Delgado Graciela et al., Mannheim

Combined use of uromodulin and eGFR to estimate cardiovascular risk

Delgado Graciela et al., Mannheim

Markers of endothelial function in smokers and non-smokers – The Ludwigshafen Risk and Cardiovascular Health Study

Delgado Graciela et al., Mannheim

The health economics of PCSK9 inhibition

Dressel A. et al., Mannheim

Non-oxidised PTH and clinical outcomes in patients with coronary artery disease

Dschietzig T et al., Berlin and Bensheim

Chylomicronemia due to homozygosity for a novel variant of GPI-anchored HDL-binding protein 1

Eirich Katharina et al., Würzburg

Information on weather conditions improve the prognostic ability of vitamin D in stable coronary artery disease

Elsner Laura et al., Bad Nauheim

Influence of atrial fibrillation burden on copeptin levels in patients undergoing pulmonary vein isolation

Elsner Laura et al., Bad Nauheim

Association between *helicobacter pylori* infection and laboratory biomarkers of iron metabolism

Enko D. et al., Leoben

Evaluation of the analytical performance of a liquid-chromatography high-resolution mass-spectrometry for the quantification of hepcidin-25 in human serum

Enko D. et al., Leoben

FH-ALERT: Laboratory guided identification of patients with familial hypercholesterolemia

Fath F. et al., Mannheim

Effects of PCSK9 inhibition on non-cholesterol sterols in a real world cohort

Fauler G. et al., Graz

Steadiness and Independence of laboratory parameters for cardiorenal risk Scoring in a large-scale review of routine practice laboratory data

Fenyvesi T. et al., Weiden

Plausibility check of the Borrelia species Serology in routine laboratory data based on CRP and in comparison with the Treponema pallidum serology

Fenyvesi T. et al., Weiden

Seeking diagnostic biomarkers for acute aortic dissection

Gawinecka Joanna et al., Zürich

Systems biology approaches to risk prediction

Gergei Ingrid et al., Mannheim

Poster Presentations

Genome wide association study of klotho

Gergei Ingrid et al., Mannheim

Implementation of the Coropredict algorithm in the laboratory environment

Grammer Tanja et al., Mannheim

Generalized lipodystrophy in a woman with diabetes mellitus and hypertriglyceridemia due to novel heterozygous mutations in LMNA and AGPAT2

Grammer Tanja et al., Mannheim

Galectin 3 – interaction with the renin-angiotensin system

Grübler M. et al., Bern

Afamin als prädiktiver Marker für Schwangerschaftskomplikationen

Dieplinger H. et al., Vienna

Cholesterol depletion impairs the contractile machinery in neonatal rat cardiomyocytes

Hissa Bárbara et al., Mannheim

Comparison of Free and Total 25-hydroxyvitamin D in Normal Human Pregnancy

Hocher B. et al., Heidelberg

Non-oxidized PTH (n-oxPTH) - but not oxidized PTH (oxPTH) -stimulates fibroblast growth factor 23 (FGF23) and increases only slightly in CKD patients

Hocher B. et al., Heidelberg

Cellular cholesterol efflux as a risk marker of atherosclerosis

Hunjadi Monika et al., Innsbruck

Prognostic role of suPAR in the AtheroGene study

Karakas M. et al., Hamburg

Diagnostic role of suPAR in BACC

Karakas M. et al., Hamburg

Prognostic role of suPAR in BACC

Karakas M. et al., Hamburg

Clinical characteristics of three cases with Cerebrotendineous xanthomatosis

Kassner Uschi et al., Berlin

Fatty acid risk score improves risk prediction in primary and secondary prevention compared to established risk prediction algorithms

Kleber M. et al., Mannheim

Prevalence of familial hypercholesterolemia in the LURIC Study estimated by the CARRENAL custom designed microarray

Kleber M. et al., Mannheim

Geno-wide polygenic score for CVD risk in persons undergoing coronary angiography

Kleber M. et al., Mannheim

A clinical case of hypobetalipoproteinemia

Klose G. et al., Bremen

Agnostic analysis of coronary angiograms reveals phenotypes associated with CVD mortality

Krohn Jona et al. Heidelberg

nutriCARD 2.0: The BMBF competence cluster for nutrition and cardiovascular health

Lorkowski S. et al., Jena

Long- and short-term association of low-grade systemic inflammation with cardiovascular mortality

Malle E. et al., Graz

Atrial fibrillation is associated with alterations in HDL function, metabolism and particle number

Marsche G. et al., Graz

Estimation of the glomerular filtration rate using SDMA as an index of kidney function

Meinitzer A. et al., Graz

Thyroid metabolism and low density lipoproteins

Merke Anette et al., Bensheim

LURIC - 20 years of follow-up

Moissl Angela et al., Mannheim

Poster Presentations

Novel inflammatory markers, kidney function and disease: results from the KORA study

Nano Jana et al., München

PEARL, a non-interventional study on real-world use of alirocumab in German clinical practice: Final study and cardiovascular subgroup data

Parhofer Klaus G. et al., Munich

Association of chromosome 9p21 with subsequent CHD events: A GENIUS-CHD study of individual participant data

Patel R., London

Telomer length and mortality in the LURIC study

Pusceddu Irene et al., Bozen

Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease.

Raedle-Hurst Tanja et al., Homburg

The haptoglobin genotype modifies the relationship between vitamin E and mortality

Renner W. et al., Graz

FH Screening in children and reverse cascade screening for FH in their parents: A population-based approach in Bavaria

Sanin Veronika et al., Munich

Chylomicron remnants predict CVD outcomes in the HCS study

Scharnagl H. et al., Graz

Troponin I and cardiovascular mortality in the getABI study

Scharnagl H. et al., Graz

Genetics of patients with clinical suspicion of familial hypercholesterolemia in a lipid outpatient unit

Schatz Ulrike et al., Dresden

Cascade Screening and Registry for High Cholesterol (CaRe-High): interim results

Schmidt Nina and Schatz Ulrike et al., Mannheim and Dresden

Interleukin-1alpha (IL-1A) is a key driver of CKD-associated vascular diseases

Schmit D. et al., Homburg

The von Willebrand factor Tyr2561 allele is a gain-of-function variant and a risk factor for early myocardial infarction

Brehm Maria et al., Hamburg

Comparison of Friedewald formula and Martin/Hopkins formula for estimating LDL cholesterol in CKD

Scheuer Anja et al., Homburg

Can the cholesterol efflux capacity predict the progression of CKD?

Scheuer Anja et al., Homburg

Urinary Dickkopf-3 (DKK3) predicts acute kidney injury and subsequent loss of kidney function in patients with cardiac surgery

Schunk S. et al., Homburg

GFR adjusted uric acid is a superior cardiovascular outcome and mortality predictor than uric acid alone

Sellin L. et al., Düsseldorf

Immune monitoring in kidney transplantation using B-cell activating factor (BAFF) and its soluble receptor BAFF-R

Shipkova Maria et al., Leinfelden Echterdingen

Interference of biotin in in-vitro diagnostics – Analysis of field safety notices published by the BfArM in Germany

Siekmeier R. et al., Mannheim

Interference of fulvestrant in in-vitro diagnostics for determination of estrogen – Analysis of field safety notices published by the BfArM in Germany

Siekmeier R. et al., Mannheim

LDL cholesterol to apolipoprotein B ratio and cardiovascular mortality

Silbernagel G. et al., Graz

Poster Presentations

Apolipoprotein C-III mediates alternative NLRP3 inflammasome activation in human monocytes

Speer T. et al., Homburg

Hypobetalipoproteinemia due to a novel mutation in APOB

Steinmetz A. et al., Nürnberg

FGF-23 and iron metabolism

Stöhr R. et al., Aachen

Graft derived cell free DNA (GcfDNA) as a marker of cell injury and rejection in kidney transplantation

Wieland E. et al., Leinfelden-Echterdingen

The BIOCLAIMS cohort: a resource for biomarker discovery and validation

Winklhofer-Roob Brigitte M. et al., Graz

A systems biological approach towards the discovery of functional biomarkers of high density lipoproteins

Yalcinkaya M. et al., Zürich

Association of CNDP1 genotype with all-cause mortality

Yard B et al., Mannheim

Effect of pulse pressure and double product on cardiovascular and overall mortality in LURIC

Yazdani B. et al., Mannheim

Measurement of vitamin D metabolites by mass spectroscopy

Zelzer Siglinde et al., Graz

A common variant in the NLRP3 inflammasome locus associates with mortality

Zewinger S. et al., Homburg

Dickkopf-3 in urine identifies patients with progressive chronic kidney disease

Zewinger S. et al., Homburg

Phenome-wide Mendelian randomization study mapping the influence of the plasma proteome on complex diseases

Zheng J. et al., Bristol



LOGISTICS

Logistics

The Cardiorenal Axis From risk stratification to personalized treatment

MEETING VENUE

Dorint Kongresshotel Mannheim
Friedrichsring 6
68161 Mannheim

MEETING TIMES

Wednesday, January 16, 2019
12:30 – 18:00

Thursday, January 17, 2019
9:00 – 18:35

Friday, January 18, 2019
8:30 – 12:30

ORGANIZERS

D·A·CH-Gesellschaft Prävention von
Herz-Kreislauf-Erkrankungen e. V.
Friedensallee 25
c/o MasterMedia GmbH
22765 Hamburg

Medizinische Klinik V
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim

SYNLAB Akademie
SYNLAB Holding Deutschland GmbH
P5,7
68161 Mannheim

ADDITIONAL POSTERS AND INFORMATION

Do you wish to contribute a poster?
Do you need other information?

PLEASE CONTACT

Univ.-Prof. Dr. med. Winfried März
SYNLAB Akademie
SYNLAB Holding Deutschland GmbH
P5,7
68161 Mannheim
Telefon +49 621 43179-432
Telefax +49 621 43179-433
E-Mail winfried.maerz@synlab.com

Prof. Dr. med. Bernhard K. Krämer
Medizinische Klinik V
Universitätsmedizin Mannheim
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Telefon +49 621 383-5172
Telefax +49 621 383-3804
E-Mail bernhard.kraemer@umm.de

Prof. Dr. med. Christoph Wanner
Universitätsklinikum Würzburg
Medizinische Klinik und Poliklinik I
Abteilung Nephrologie
Oberdürrbacher Straße 6
97080 Würzburg
Telefon +49 931 201-39030
Telefax +49 931 201-639030
E-Mail Wanner_C@ukw.de

SPONSORS



Sponsors

The Cardiorenal Axis From risk stratification to personalized treatment

MAIN SPONSOR

AMGEN GmbH
16.000 Euro



SPONSORS

Abbott GmbH & Co. KG
1.000 Euro



Aegerion Pharmaceuticals GmbH
500 Euro



Akcea Therapeutics
5.000 Euro



Alexion Pharma Germany GmbH
1.000 Euro



Axon Lab AG
1.500 Euro



BASF – The Chemical Company
1.000 Euro



Bayer Vital GmbH
1.500 Euro



bestbion dx GmbH &
sphingotec GmbH
1.500 Euro



Boehringer Ingelheim Pharma
GmbH & Co. KG
10.000 Euro



Immundiagnostik AG
500 Euro



Merck Chemicals GmbH
2.000 Euro



MSD Sharp & Dohme GmbH
1.000 Euro



Novartis Pharma GmbH
1.000 Euro



numares AG
1.000 Euro



Ocupharm GmbH
1.000 Euro



Olink Proteomics
10.000 Euro



Sanofi-Aventis Deutschland GmbH
5.000 Euro



Sanofi Gruppe – Genzyme GmbH
2.500 Euro



Siemens Healthcare
Diagnostics GmbH
1.000 Euro



Registration

The Cardiorenal Axis From risk stratification to personalized treatment

Please issue your binding registration by 22.12.2018 latest to www.synlab.com/de/mensch/fortbildung, by e-mail to manuela.hormuth@synlab.com or winfried.maerz@synlab.com or by **fax to +49 (0)621 43179-433**.

CONTACT

SYNLAB Akademie
SYNLAB Holding Deutschland GmbH
P5, 7
68161 Mannheim

Telefon +49 (0)621 43179-432
Telefax +49 (0)621 43179-433
E-Mail manuela.hormuth@synlab.com
winfried.maerz@synlab.com

We kindly ask you for binding registration, as non-attendance will generate avoidable costs for the organizers.

PARTICIPATION SYMPOSIA

I will participate with ___ person(s) on the following days

___ person(s) on 16.01.2019

___ person(s) on 17.01.2019

___ person(s) on 18.01.2019

PARTICIPATION EVENING EVENTS

Olink – 16.01.2019 *only possible upon participation in the Olink satellite meeting*

Get together – 17.01.2019

OVERNIGHT STAYS

Number of nights ___

Arrival 16.01.2019

Arrival 17.01.2019

Please provide information completely and clearly

Address

Telephone and fax

E-mail

Participant name(s)

Date, signature, and stamp

Notes



Der/Die Veranstalter sichern zu, dass die Fortbildungsmaßnahme produkt- und/oder dienstleistungsneutral gestaltet wird. Wissenschaftliche Leitung und Referenten werden mögliche Interessenskonflikte, die die Inhalte der Fortbildungsmaßnahme betreffen, in ihren Beiträgen offen legen.

Hinweise zum Datenschutz

Die SYNLAB Holding Deutschland GmbH behandelt personenbezogene Daten im Einklang mit den Regeln der Allgemeinen Datenschutz-Grundverordnung vom 25. Mai 2018. Sie finden die Datenschutzerklärung hier www.synlab.de/de/datenschutz/. Diese Einladung erhalten Sie im Auftrag der SYNLAB Holding Deutschland GmbH vom Schwarzeck Verlag GmbH, Einsteinring 24, 85609 Aschheim, der Ihre Anschrift aus dem Adressverzeichnis der ONEKEY Datenbank IQVIA Commercial GmbH & Co. OHG, Unterschweinstiege 2-14, 60549 Frankfurt bezieht. Wie auch bisher haben Sie die Möglichkeit, der Zusendung von Einladungen zu Veranstaltungen der SYNLAB Akademie zu widersprechen, entweder schriftlich an SYNLAB Akademie für ärztliche Fortbildungen, p5, 7, 68161 Mannheim, Telefon: 0621 43179432, Fax: 0621 43179433 oder durch elektronische Mitteilung an fortbildungen.akademie@synlab.com. Die SYNLAB Akademie wird im Fall des Widerspruchs dafür Sorge tragen, dass Sie künftig keine weiteren Einladungen erhalten werden. Als Geschäftsbereich der SYNLAB Holding Deutschland GmbH speichert und verarbeitet die SYNLAB Akademie Ihre persönlichen Daten erst ab demjenigen Zeitpunkt, an dem Sie sich für die Teilnahme zu einer Veranstaltung anmelden. Speicherung und Verarbeitung Ihrer persönlichen Daten erfolgen dann nur zum Zweck der Durchführung der jeweiligen Veranstaltung.



© SYNLAB Holding Deutschland GmbH · Keine Haftung für Irrtümer, Fehler und falsche Preisangaben. Änderungen bleiben vorbehalten. Alle Texte, Fotos und Inhalte unterliegen dem Urheberrecht. Keine Verwendung ohne ausdrückliche Erlaubnis des Rechteinhabers.